[{"id":"a82c37b0-b7de-4909-9ed6-4017ba0331ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00620633","created_at":"2021-01-18T02:18:25.353Z","updated_at":"2024-07-02T16:36:33.932Z","phase":"Phase 1","brief_title":"Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation","source_id_and_acronym":"NCT00620633","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1","pipe":" | ","alterations":" WT1 overexpression","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATA520"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2008","start_date":" 02/08/2008","primary_txt":" Primary completion: 02/26/2021","primary_completion_date":" 02/26/2021","study_txt":" Completion: 02/26/2021","study_completion_date":" 02/26/2021","last_update_posted":"2021-03-02"},{"id":"c3cf462d-4934-463f-b884-5910698b124d","acronym":"INTACT-WT1","url":"https://clinicaltrials.gov/study/NCT02895412","created_at":"2021-02-01T11:52:59.768Z","updated_at":"2024-07-02T16:37:29.234Z","phase":"Phase 1","brief_title":"Infection and Tumour Antigen Cellular Therapy","source_id_and_acronym":"NCT02895412 - INTACT-WT1","lead_sponsor":"University of Sydney","biomarkers":" WT1","pipe":" | ","alterations":" WT1 overexpression","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 overexpression"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2016-09-09"}]